Zevra Therapeutics (ZVRA) Long-Term Deferred Tax (2014 - 2019)

Zevra Therapeutics' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $67.7 million for Q4 2019.

• Quarterly Long-Term Deferred Tax rose 32.1% year-over-year to $67.7 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $67.7 million (up 32.1% YoY) and the FY2019 annual result came in at $67.7 million, up 32.1% from the prior year.
• Long-Term Deferred Tax was $67.7 million for Q4 2019 at Zevra Therapeutics, up from $51.3 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $67.7 million in Q4 2019 and bottomed at $29.1 million in Q4 2015.
• A 5-year average of $46.0 million and a median of $45.0 million in 2016 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2015 — Long-Term Deferred Tax jumped 77.57% — and 2017, when it fell 17.69%.
• Zevra Therapeutics' Long-Term Deferred Tax stood at $29.1 million in 2015, then surged by 54.57% to $45.0 million in 2016, then dropped by 17.69% to $37.0 million in 2017, then jumped by 38.46% to $51.3 million in 2018, then surged by 32.1% to $67.7 million in 2019.
• Business Quant data shows ZVRA's Long-Term Deferred Tax at $67.7 million in Q4 2019, $51.3 million in Q4 2018, and $37.0 million in Q4 2017.